LXR inverse agonists for treatment of cancer
US11746097B2 · kind B2 · utility
0Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 23, 2017 |
| Grant date | Sep 5, 2023 |
| Priority date | — |
| Expiry date | Nov 7, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0053
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In some aspects, the present disclosure provides compounds of the formula: (I) or (II) wherein the variables are as defined herein. In some embodiments, these compounds may be used to treat cancer or other hyperproliferative diseases, as well as atherosclerosis and coronary artery disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.